Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. 2016

Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet and Karolinska University Hospital, Huddinge, Sweden; Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital, Huddinge, Sweden.

We wanted to determine whether allogeneic hematopoietic stem cell transplantation (HSCT) may result in long-term survival in patients with solid cancer. HSCT was performed in 61 patients with solid cancer: metastatic renal carcinoma (n = 22), cholangiocarcinoma (n = 17), colon carcinoma (n = 15), prostate cancer (n = 3), pancreatic adenocarcinoma (n = 3), or breast cancer (n = 1). Liver transplantation was performed for tumor debulking in 18 patients. Median age was 56 years (range, 28 to 77). Donors were either HLA-identical siblings (n = 29) or unrelated (n = 32). Conditioning was nonmyeloablative (n = 23), reduced (n = 36), or myeloablative (n = 2). Graft failure occurred in 13 patients (21%). The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV was 47%, and that of chronic GVHD was 32%. Treatment-related mortality was 21%. At 5 years cancer-related mortality was 63%. Currently, 6 patients are alive, 2 with renal cell carcinoma, 1 with cholangiocarcinoma, and 3 with pancreatic carcinoma. Eight-year survival was 12%. Risk factors for mortality were nonmyeloablative conditioning (HR, 2.95; P < .001), absence of chronic GVHD (HR, 3.57; P < .001), acute GVHD of grades II to IV (HR, 2.90; P = .002), and HLA-identical transplant (HR, 5.00; P = .03). With none of these risk factors, survival at 6 years was 50% (n = 6). Long-term survival can be achieved in some patients with solid cancer after HSCT.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females

Related Publications

Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
March 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
January 2021, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
September 2008, Clinical rheumatology,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
July 2022, Bone marrow transplantation,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
January 2015, Deutsches Arzteblatt international,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
March 2010, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
December 2008, La Revue du praticien,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
February 2019, Archives of sexual behavior,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
November 2021, HemaSphere,
Brigitta Omazic, and Mats Remberger, and Lisbeth Barkholt, and Gunnar Söderdahl, and Zuzana Potácová, and Peter Wersäll, and Bo-Göran Ericzon, and Jonas Mattsson, and Olle Ringdén
February 2019, Haematologica,
Copied contents to your clipboard!